Nucleus' artificial intelligence formulation platform allows for the creation of optimized media that will provide Cognate's clients with reduced development times to speed candidates toward large-scale production. The partnership will improve the stability, reproducibility, and supply-chain integrity for clients by enabling on-demand supply of culture media on both the clinical and commercial scales.

The partnership will focus on providing both allogeneic and autologous on-demand cell and gene therapies. The Nucleus platform is unique because it is scalable and allows for rapid optimization of media and rapid production of custom media lots. Cognate plans to implement this technology across its global capacity network.

Cognate BioServices expands manufacturing in U.S., Europe
Contract development and manufacturing organization Cognate BioServices plans to expand cell and gene therapy manufacturing capacity, laboratory space,...